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Abstract
Background: Sub-optimal adherence to warfarin places millions of patients at risk for stroke and bleeding
complications each year. Novel methods are needed to improve adherence for warfarin. We conducted two pilot
studies to determine whether a lottery-based daily financial incentive is feasible and improves warfarin adherence
and anticoagulation control.
Methods: Volunteers from the University of Pennsylvania Anticoagulation Management Center who had taken
warfarin for at least 3 months participated in either a pilot study with a lottery with a daily expected value of $5
(N = 10) or a daily expected value of $3 (N = 10). All subjects received use of an Informedix Med-eMonitor™
System with a daily reminder feature. If subjects opened up their pill compartments appropriately, they were
entered into a daily lottery with a 1 in 5 chance of winning $10 and a 1 in 100 chance of winning $100 (pilot 1)
or a 1 in 10 chance of winning $10 and a 1 in 100 chance of winning $100 (pilot 2). The primary study outcome
was proportion of incorrect warfarin doses. The secondary outcome was proportion of INR measurements not
within therapeutic range. Within-subject pre-post comparisons were done of INR measurements with
comparisons with either historic means or within-subject comparisons of incorrect warfarin doses.
Results: In the first pilot, the percent of out-of-range INRs decreased from 35.0% to 12.2% during the
intervention, before increasing to 42% post-intervention. The mean proportion of incorrect pills taken during the
intervention was 2.3% incorrect pills, compared with a historic mean of 22% incorrect pill taking in this clinic
population. Among the five subjects who also had MEMS cap adherence data from warfarin use in our prior study,
mean incorrect pill taking decreased from 26% pre-pilot to 2.8% in the pilot. In the second pilot, the time out of
INR range decreased from 65.0% to 40.4%, with the proportion of mean incorrect pill taking dropping to 1.6%.
Conclusion: A daily lottery-based financial incentive demonstrated the potential for significant improvements in
missed doses of warfarin and time out of INR range. Further testing should be done of this approach to determine
its effectiveness and potential application to both warfarin and other chronic medications.
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Medical conditions known to increase the risk of throm-
boembolism (TE) affect millions of patients worldwide
each year [1], with substantial associated morbidity and
mortality [2-7]. Warfarin is recommended for the major-
ity of these patients [8-12] and, when used properly, dra-
matically reduces the risk of embolic events [13].
However, despite its manifest benefits, poor control of
anticoagulation levels is fairly common. Even in standard-
of-care anticoagulation clinics devoted to monitoring
patients on warfarin, [1] 32% to 68% of patient-time is
spent out of the target therapeutic range, and poor adher-
ence is a strong contributor [14-16]. One recent cohort
study found that 40% of subjects missed 20% or more of
their warfarin doses [17]. Inadequate regulation of antico-
agulation levels reduces the drug's benefit, and can pro-
duce side-effects and create physician reluctance to
prescribe warfarin in the first place [18,19]. Novel and
scalable methods for improving adherence are needed to
improve both the safety and effectiveness of warfarin.
Lotteries, which are extremely popular among Americans
[20], are a potentially cost-effective way to deliver finan-
cial rewards to subjects and thereby improve adherence.
More than 50% of adults residing in States with lotteries
play at least once a year, spending a total of $48 billion
($166 per person).
We undertook two pilot studies that tested the feasibility
and potential effectiveness of a novel approach to improv-
ing warfarin adherence and anticoagulation control that
involves daily lottery incentives and makes use of a com-
puterized pill-box that could enhance the scalability of the
approach. This is the first test ever undertaken of a daily
lottery to improve medication adherence and draws on a
number of insights from the field of behavioral econom-
ics, including the importance of frequent feedback and
incentives [21,22], the greater motivational power of lot-
teries over similarly valued certain payments [23], and the
motivating force of anticipated regret [24].
Methods
Study population
Patients, 21 years or older, with ongoing care at the Hos-
pital of the University of Pennsylvania Anticoagulation
Management Center were invited to participate in the
study, which was approved by the Institutional Review
Board of the University of Pennsylvania. Ten patients who
had been taking warfarin for at least 3 months partici-
pated in each of the two pilot studies. To participate, sub-
jects had to provide written consent, have a home
telephone line (to connect the monitor), and be capable
of using the pill monitor.
Study procedures
Each subject was provided with an Informedix Med-
eMonitor™ System, which has a display screen and sepa-
rate medication compartments. The device was pro-
grammed to communicate by telephone with a central
database accessible by the study's administrator. Partici-
pants were enrolled in a daily lottery and followed for 3
months. Each subject was assigned a 2-digit number upon
entry into the study, e.g., "27". In the first pilot, the
expected value per day of the lottery was $5, which was
comprised of a 2 in 5 chance at a $10 reward (e.g., either
2 or 7 is selected as the first or second digit) and 1 in 100
chance at $100 reward (e.g., '27' is selected). In the second
pilot, conducted with a new group of subjects meeting the
same enrollment criteria, the lottery had an expected daily
value of $3, which was comprised of a 1 in 5 chance at a
$10 reward (e.g., either 2 is selected as the first digit or 7
as the second digit) and 1 in 100 chance at $100 reward.
Although patients were enrolled in the lottery each day
that they were instructed to take a pill, they were only eli-
gible to receive payment if the Med-eMonitor indicated
they had opened the pill compartment and confirmed
that they took their warfarin as prescribed. If a patient was
told to not take warfarin on a particular day they would
only be ineligible if they failed to comply by opening the
compartment and taking a pill that day. Patients who were
ineligible based on nonadherence who won the lottery
were notified that they won and would have been paid,
had they taken their medication. The Med-eMonitor was
also programmed to provide a daily reminder chime, but
no other reminder messages.
Measurement of outcomes
The primary outcome measured was the proportion of out
of range INRs, based on the subjects' prescribed INR
range. The secondary outcome was patient adherence, cal-
culated as "mean correct patient pill taking" based on the
percentage of days in which each patient correctly opened
the correct compartment and recorded pill taking.
Statistical analysis
Analyses quantified each subject's adherence during the
intervention, and compared that with either historical
group controls or their own personal history, both as
measured by Medication Event Monitoring System®
(MEMS) cap usage from a prior study [17]. We examined
the proportion of INRs out of range during the interven-
tion and compared these with the proportion of INRs out
of range in the same patients for the 3 INRs immediately
preceding and immediately following the intervention.
Results
All patients were able to set-up and use the monitors suc-
cessfully in their homes. The first pilot (expected value of
lottery $5 per day) included 979 patient-days of warfarinPage 2 of 6
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mean proportion of incorrect pills taken was only 2.3%
incorrect pills, compared with a historic mean of 22%
incorrect pill taking in this clinic population (Figure 1).
Mean adherence ranged from 92 to 100% (0–8% incor-
rect pills taken) per patient. Five of these patients also had
MEMS cap adherence data from warfarin use in our prior
study, and their mean incorrect pill taking decreased from
26% pre-pilot to 2.8% in the pilot. In the second pilot
study (expected value of lottery $3 per day), an additional
10 patients contributed a total of 813 days of warfarin use
(mean 81.3, range 14–103). Mean adherence was 98.4%
(only 1.6% incorrect pills taken). Mean adherence ranged
from 92.1% to 100%, similar to the $5/day pilot (Figure
1). Two of these patients had MEMS Cap adherence data
from a prior warfarin study, one with 27.9% incorrect
dosing and one with 6.4%.
There was a substantial improvement in out of range INRs
during both studies (Figure 2). In the first pilot the pro-
portion of out of range INRs decreased from 35.0% pre-
pilot to 12.2% post-pilot, a 65.2% improvement. In the
post-intervention period, the proportion of INRs out of
range increased back to close to the baseline value (Figure
2). In the second pilot, INRs out of range decreased from
65.0% to 40.4%, a 37.9% improvement, and again
increased back to close to baseline post-intervention (Fig-
ure 2).
Only one of 20 patients developed a new elevation in INR
on the first INR measurement after beginning pilot (INR
was 3.3), suggesting that improvement in adherence
among previously poorly adherent patients did not result
in new over-anticoagulation. Four patients (1 in the first
pilot and 3 in the 2nd pilot) had an INR above target range
at enrollment. In all four of these patients, their INR was
within range by the time of the 2nd follow-up visit. There
were no serious adverse events among any of the partici-
pants.
Discussion
In two small-scale studies, we demonstrate that a lottery-
based financial incentive coupled with a simple reminder
system substantially improved the rate of non-adherence
to warfarin compared with historic controls, accompanied
by a large improvement in anticoagulation control rela-
tive to their baseline values at a state-of-the-art anticoagu-
lation clinic, While there is controversy about whether
such payments to patients should be used [25,26], the
degree of improvement observed in non-adherence rates
in this pilot is striking.
The fact that subjects' proportion of INRs out of range
returned to close to their baseline values post-intervention
indicates that while the lottery-based incentive appeared
to be effective in improving anticoagulation control,
longer-term administration of the incentive program is
likely necessary. It would be important to know whether
Adherence under lotteries compared to historic controlsFigur  1
Adherence under lotteries compared to historic controls.
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administration of the intervention; for example, would
people internalize improved medication taking habits if
the intervention were longer-standing? It is also possible
that longer-range administration of the adherence-
improving intervention may be necessary to sustained
improved adherence. Longer-term administration of this
intervention could be cost effective for high-risk patients
on warfarin given the high risk of stroke and other throm-
botic complications.
Lotteries used as incentives have had some success in
altering health behaviors [27,28]. Small payouts, e.g., $10
to quit smoking, may not be effective [28], but knowledge
about the effectiveness of lotteries in this regard is limited,
as nearly all lottery-based studies to date have used
rewards with low expected values and did not provide
daily payouts. In the only study to have previously used
daily lotteries, our group found that a lottery similar in
design to the lottery used in this study with an expected
value of $3 per day led to significant amounts of weight
loss relative to a control group[29] Lotteries with larger
expected values and daily lotteries, to our knowledge,
have never been tested in the context of medication adher-
ence.
The lottery incentive was designed to take advantage of
several effects identified in the behavioral economics liter-
ature on incentives. First, consistent with research show-
ing that even small rewards and punishments can have
great incentive value if they occur immediately
[21,22,30,31], adherent patients received rapid feedback
about whether they won and non-adherent subjects
received feedback about whether they would have won
had they been adherent. Second, based on research show-
ing that people are motivated by the experience of past
Differences in time out-of-range INRs while in lottery compared to pre-enrollmentFigu  2
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people are particularly emotionally attracted to small
probabilities of large rewards [33], the lottery was tailored
to provide frequent small payoffs (a 1 or 2 in 5 chance at
a $10 reward) and infrequent large payoffs (a 1 in 100
chance at a $100 reward). Third, research on decision
making has found that the desire to avoid regret is a
potent force in decision making under risk [23,34]. By giv-
ing non-adherent patients feedback about what they
would have won had they been adherent, the incentive
scheme was designed to maximize the threat of regret if
people failed to adhere. Lotteries may be more effective
than fixed payments (e.g. $3 per day), as people tend to
overweigh small probabilities in making decisions
[23,35] and playing a daily lottery may have entertain-
ment value that offsets some of the tedium of taking daily
medications.
The major limitation of this study is that it was not con-
ducted as a randomized controlled trial. However, the
within-subject improvement in INRs as well as the
improvements in adherence both among subjects in
whom we had MEMS cap adherence data pre-intervention
and compared to historical controls were quite large.
Nonetheless, demonstration of the effectiveness of this
intervention will ultimately require a randomized trial
ideally with longer-term follow-up to examine the sus-
tainability of this approach. Examination of cost effective-
ness will also be important to determine the likelihood of
adoption by payers.
The success of the intervention raises ethical issues. First,
there could be an objection to paying people to 'do things
that they should do anyway.' However, the behavioral
economics literature finds that even highly motivated
individuals often have difficulty in making decisions in
the short term that favor their long-term interests [36]. A
lottery (or other reward system that provides frequent
positive reinforcement) can be thought of as a way to help
patients to internalize these long-term benefits so they
make decisions in the short-term that favor their long-
term interests. From the standpoint of a payor, a similar
amount of money could be used to treat strokes that result
from non-use of warfarin, or to provide an incentive sys-
tem like this, which reduces the rate of strokes, which is
clearly a better outcome for the patients. Second there
could be a concern that rewarding patients to take medi-
cation could reduce their sense of personal responsibility
for their health and hence adherence if and when incen-
tives are removed. However, our study provided no evi-
dence of such a negative rebound effect, and it may be true
that any long-term changes in behavior induced by incen-
tives would persist due to the establishment of adherent
habits.
Conclusion
These studies provide initial evidence of the feasibility
and potential promise of a lottery-based financial incen-
tive in improving medication adherence for patients using
warfarin. Given the prevalence of conditions necessitating
warfarin use, high rates of non-adherence, and attendant
consequences for patient morbidity and mortality, this
approach shows great promise and merits further testing.
This novel approach could potentially also be utilized to
improve medication adherence for a wide range of other
chronic conditions that require ongoing use of medica-
tions.
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